A carregar...

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

BACKGROUND: The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS: We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic muta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Welch, John S., Petti, Allegra A., Miller, Christopher A., Fronick, Catrina C., O'Laughlin, Michelle, Fulton, Robert S., Wilson, Richard K., Baty, Jack D., Duncavage, Eric J., Tandon, Bevan, Lee, Yi-Shan, Wartman, Lukas D., Uy, Geoffrey L., Ghobadi, Armin, Tomasson, Michael H., Pusic, Iskra, Romee, Rizwan, Fehniger, Todd A., Stockerl-Goldstein, Keith E., Vij, Ravi, Oh, Stephen T., Abboud, Camille N., Cashen, Amanda F., Schroeder, Mark A., Jacoby, Meagan A., Heath, Sharon E., Luber, Kierstin, Janke, Megan R., Hantel, Andrew, Khan, Niloufer, Sukhanova, Madina J., Knoebel, Randall W., Stock, Wendy, Graubert, Timothy A., Walter, Matthew J., Westervelt, Peter, Link, Daniel C., DiPersio, John F., Ley, Timothy J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217532/
https://ncbi.nlm.nih.gov/pubmed/27959731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1605949
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!